Search results for: 'development body iot'

Microbiome research is on the rise following technological advancements and significant cost reductions in microbiome analysis. Research has unlocked the potential of microbiome in medical use cases, yielding tremendous insights on its nature, interactions, and impact within a host and in an external environment. Advanced studies on the role of mic...

By 2023, biologics constituted 44% of the therapeutic pipeline, with antibodies and recombinant proteins as leading categories. Nevertheless, advancements in these fields decelerated, with most of the expansion happening in heterologous cell treatments, synthetic nucleic acids, and viruses. The global biologics pipeline will shift toward more compl...

The global pharmaceutical research and development (R&D) pipeline accounts for more than 21,000 molecules, as of April 2023, indicating a 5.8% hike over 2022, with more than 6,100 molecules in active development. In general, however, the pharma/biopharma industry has stagnated with respect to R&D activity. Overall R&D expenditure totals about $276....

The convergence of IoT and healthcare, known as the internet of medical things (IoMT), is transforming the healthcare landscape, bringing unprecedented connectivity and convenience. However, the rapid proliferation of IoT devices in healthcare exposes critical data security and cybersecurity risks. This Frost & Sullivan study explores data security...

Scope of the report The research report includes the following segments: Product scope: Automotive Powertrain, Chassis, Body, and Materials Roadmaps Geographic scope: Global End-user scope: Passenger vehicle OEMs and suppliers The research provides an overview of the automotive powertrain, chassis, body, and materials roadmaps. It includes...

The global small‑molecule CDMO industry is undergoing a structural transformation driven by increasing molecular complexity, patent expiries, cost pressures, and the strategic need to secure resilient pharmaceutical supply chains. Demand is shifting beyond high‑volume commodity generics toward specialized development and manufacturing capabilities ...

In a highly competitive market with increasing regulatory pressures, Frost & Sullivan has analyzed the current state of the Internet of Medical Things (IoMT) security industry and presents the results of its research in this Frost Radar™, a benchmarking system to spark companies to action according to parameters of growth and innovation. The repo...

This edition of the Life Science, Health & Wellness Technology Opportunity Engine (TOE) provides actionable insights across new developments in prebiotics, immunology, oncology, cell and gene therapies, antibody therapies, and precision medicine approaches. The TOE also encompasses technology advances across the use of AI and ML in drug discovery a...

02 May 2023  |  Global  |  Technology Research

Technology Advances in Senolytics

Innovative Drug Development Culture Working to Prolong Health Spans and Eliminate Aging Cells

Infographics

×

Senolytics is a relatively new field of development that falls under the broad category of senotherapeutics, along with senomorphics and senostatics. Although nascent, the field could address the root causes of most chronic conditions brought on by aging as it clears senescent cells that have ceased to multiply (and ideally are eliminated from the ...